Avient Earnings Call: Key Takeaways
Avient delivered a strong Q2 2026 beat driven by unexpected volume growth and record 18.3% EBITDA margins, leading to a full-year guidance raise across EBITDA, EPS, and free cash flow.
- Call
- Nov 4, 2026, 8:00 AM ET
ALFA USA Filings
Every alert, straight from SEC EDGAR
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Avient Corp filings on SEC EDGAR ↗
Filing type
Alerts
Time
4 alerts
Avient delivered a strong Q2 2026 beat driven by unexpected volume growth and record 18.3% EBITDA margins, leading to a full-year guidance raise across EBITDA, EPS, and free cash flow.
Avient Corporation reported a significant increase in net income for the nine months ended September 30, 2026, reaching $165.0 million compared to $66.4 million in the prior year period. Sales grew to $2,655.6 million, and operating income rose to $290.8 million, driven by higher gross margins and lower selling and administrative expenses relative to the previous year.
Avient Corporation reported third quarter 2026 sales of $891 million, a 10.5% increase year-over-year, driven by organic growth in packaging, healthcare, and building & construction markets. The company raised its full-year 2026 adjusted EPS guidance to a range of $3.22 to $3.32 and reported year-to-date debt reduction of $100 million.
“Our teams delivered a strong third quarter, driven by sales growth across nearly all our markets, in particular packaging, healthcare and building & construction.”
Mike Frank, President and Chief Executive Officer
“Supported by our year-to-date results and visibility into fourth quarter demand, we are narrowing our full-year 2026 adjusted EBITDA guidance to $593 to $603 million and raising our adjusted EPS guidance to $3.22 to $3.32, representing 9% to 11% adjusted EBITDA growth and 14% to 18% adjusted EPS growth for the year.”
Joe Di Salvo, Senior Vice President and Chief Financial Officer
Avient Corporation appointed Michael J. Frank as President and Chief Executive Officer and a member of the Board, effective October 7, 2026. Mr. Frank succeeds Dr. Ashish K. Khandpur, who stepped down from his role but will remain as an advisor through the end of 2026 to facilitate the transition. Richard H. Fearon was also appointed as Non-Executive Chairman of the Board.